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I. Chemical Synthesis: Materials and Methods
Compounds 4-9 were prepared as previously described. 1 Iodobenzene diacetate (PIDA) and bis(trifluoroacetoxy)iodobenzene (PIFA) were purchased from Acros. All other compounds were purchased from commercial sources and used as received, unless otherwise specified.
Thin-layer chromatography (TLC) was performed using plates pre-coated with silica gel XHL w/UV254 (250 mm) or alumina w/UV purchased from Sorbent Technologies and visualized by UV light, KMnO 4 , or anisaldehyde stains, followed by heating. ICN Silica gel (particle size 32-63 µm) was used for flash chromatography.
1 H and 13 C NMR spectra were recorded on a Varian Inova 300 (operating at 300 MHz and 75 MHz respectively) or Varian Inova 500 (operating at 500 MHz and 125 MHz respectively), and are reported relative to residual solvent peak (δ 7.26 and δ 77.2 for 1 H and 13 C in CDCl 3 , δ7.16 and δ 128.0 for 1 H and 13 C in C 6 D 6 , respectively). Data for 1 H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Spectra obtained are described using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, hept = heptuplet, m = multiplet. IR spectra were recorded on a MIDAC Corporation M Series spectrometer and samples were prepared by evaporation from CHCl 3 or CH 2 Cl 2 . High resolution mass spectra were obtained from the University of Minnesota Mass Spectrometry Facility. Chiral HPLC analysis was performed with an Agilent 1200
Series HPLC equipped with a diode array detector and 6-position column changer. Analysis of 11 and 11* was conducted with a Chiralcel OD column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd with visualization at 225 nm. 4-methyl-4-(prop-2-yn-1-yloxy)cyclohexa-2,5-dienone (S1). A solution of p-cresol (540.7 mg, 5 mmol) in propargyl alcohol (10 mL) was cooled to 0 ºC and treated with PIDA (1.61 g, 5 mmol). The reaction mixture was stirred at the same temperature for about 30 min before concentrating in vacuo.
II. Chemical Synthesis: Experimental Procedures
(1) Tello-Aburto, R; Harned, A. M. Org. Lett. 2009, 11, 3998-4000. 
S3
Residual product was purified using 9:1 hexanes-EtOAc to give 381.9 mg of the title compound in 47%
yield.
IR (neat) 3236, 2925, 2863, 2122, 1669, 1632, 1449, 1380, 1078, 1042, 862, 711 
4-methyl-4-((3-phenylprop-2-yn-1-yl)oxy)cyclohexa-2,5-dienone (S2).
A mixture of alkyne S1 (290.6 mg, 1.79 mmol) and iodobenzene (0.22 mL, 1.97 mmol) was dissolved in 10 mL of freshly distilled Et 3 N.
The solution was added to a flask containing CuI (1.7 mg, 0.0089 mmol) and Pd(Ph 3 P) 2 Cl 2 (12.5 mg, 0.017 mmol) kept under N 2 . The reaction mixture was stirred at room temperature for 12 h before diluting with 50 mL of Et 2 O. The solution was washed with 10% HCl solution (20 mL), then with water (20 mL) and brine (20 mL), dried over MgSO 4 , filtered and concentrated. Crude product was purified by flash column chromatography (FCC) using 5:1 hexanes-EtOAc to give 301.3 mg of the title compound in 70% yield.
IR (neat) 3048, 2979, 2930, 2854, 1668, 1630, 1493, 1443, 1382, 1078, 1040, 863, 759, 695 IR (neat) 3036, 2359, 2336, 1665, 1624, 1447, 1276, 1169, 1052, 922, 753, 693 
12
(Z)-(7α-methyl-5-oxohexahydrobenzofuran-3(2H)-ylidene)(phenyl)methyl acetate (12). Compound 10 (25.8 mg, 0.0865 mmol) was dissolved in 2 mL EtOAc and 10% Pd/C (11.0 mg, 0.0134 mmol, 15 mol%) was added. The reaction vessel was evacuated under gentle vacuum and backfilled with H 2 (balloon) three times. The mixture was stirred at ambient temperature for 1.5 hours at which time TLC (2x 3:1 hexane/EtOAc) indicated completed conversion. The mixture was filtered through a short plug of silica gel and eluted with fresh EtOAc. The filtrate was concentrated in vacuo. The crude product was purified by FCC using 4:1 hexanes-EtOAc to give 24.8 mg of the title compound in 95% yield as a colorless oil. 3058, 3023, 2967, 2932, 2862, 1757, 1717, 1371, 1205, 1054, 774, 704 cm 
IR (neat)

VI. Preparation of Stock Solutions of Compounds 4-12
Compound stock solutions were prepared in DMSO (100 mM or 200 mM concentrations) and stored at -20° C when not in use. Compound purities were assessed frequently by analytical reverse-phase HPLC analysis and fresh solutions were prepared as needed.
VII. Protocol for Mammalian Cell Culture
All cell lines were maintained in a humidified 5% CO 2 environment at 37 °C. CCRF-CEM cells (ATCC, CCL-119) were cultured in RPMI-1640 media (ATCC) supplemented with 10% fetal bovine serum (FBS, Gibco), penicillin (100 I.U./mL), and streptomycin (100 μg/mL, ATCC) at a density of 2 × 10 5 -2 × 10 6 cells/mL. A549/NF-κB-luc cells (Panomics, RC0002) were cultured in DMEM media (ATCC)
supplemented with 10% FBS (Gibco), penicillin (100 I.U./mL), streptomycin (100 μg/mL, ATCC), and hygromycin (100 μg/mL, Roche). DU-145 cells (ATCC, HTB-81) were cultured in EMEM media (ATCC)
supplemented with 10% FBS (Gibco), penicillin (100 I.U./mL), and streptomycin (100 μg/mL, ATCC).
Vero cells (ATCC, CCL-81) were cultured in EMEM media (ATCC) supplemented with 10% FBS, penicillin (100 I.U./mL), and streptomycin (100 μg/mL). RWPE-1 cells (ATCC, CRL-11609), which are S9 non-cancerous prostate epithelial cells, were cultured in Keratinocyte Serum-Free Medium (K-SFM; Gibco) supplemented with human recombinant epidermal growth factor (EGF, 5 ng/mL, PeproTech), bovine pituitary extract (BPE, 0.05 mg/mL, PeproTech), penicillin (100 I.U./mL, ATCC), and streptomycin (100 μg/mL, ATCC).
VIII. Protocol for NF-κB Reporter Assay
A549/NF-κB-luc cells were seeded at a density of 5,000 cells/well in cell culture media (50 μL) in 96-well white plates with clear bottoms (Costar) 24 h prior to treatment. Compounds were serially diluted in pre-warmed media and dosed to cells (final volume/well = 100 μL; final DMSO concentration = 0.5%). Thirty minutes after treating the cells, NF-κB was induced by adding TNF-α (15 ng/mL final concentration, delivered in PBS; Invitrogen) to the treated wells and the induced control wells. PBS alone was delivered to the blank and non-induced wells. After 7 h, Bright-Glo luciferase reagent (Promega) was added to each well (100 μL) and the plate was allowed to stand for two minutes.
Luminescence measurements were then obtained using an LJL BioSystems HT Analyst plate reader.
Background luminescence from reagents (no cell controls) was subtracted. Typical induction yields were ~7-fold. Negligible decreases in cell viability (<15%) were observed with test compounds under these conditions, as measured by colorimetric viability staining (Alamar Blue, Invitrogen). Figure S2 depicts the changes in cell viabilities following treatment with analogues 10, 11, and 12 in this system. DU-145 cells were then trypsinized and pelleted, and CCRF-CEM cells were immediately pelleted (500 x g for 5 min, room temperature). The media was decanted and cell pellets were resuspended once in ice-cold phosphate buffered saline (PBS, 1 mL) and pelleted again (500 x g for 5 min, 4 °C). Cell pellets were subsequently lysed in Buffer 1 (400 μL; Buffer 1 components (to make 50 mL): 10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, and one tablet of cOmplete (Roche) EDTA-free protease inhibitor cocktail) and incubated on ice for 10 min. The cells were homogenized by passing them through a 28-gauge syringe four times. Cell nuclei were pelleted by centrifugation at maximum speed (21,000 x g) for (4) Cogswell, P.; Mayo, M.; Baldwin, A. J. Exp. Med. 1997, 185, 491-497 -80 °C until further use. The residual pellets were gently washed with PBS without pellet disruption (200 μL) and subsequently resuspended in Buffer 2 (400 μL; Buffer 2 components (to make 50 mL): 20 mM HEPES, 600 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, 0.2 mM EDTA, 25% (v/v) glycerol, and one tablet of cOmplete [Roche] EDTA-free protease inhibitor cocktail) to lyse the nuclei. Samples were incubated on ice and vortexed on the highest setting for 15 sec every 10 min for a total of 40 min. The suspension was centrifuged at maximum speed (21,000 x g) for 10 min at 4 °C. The supernatants (nuclear extracts)
were collected in pre-chilled tubes and stored at -80 °C until further use. The protein concentrations were determined using the BCA protein assay kit (Pierce).
Samples of nuclear and cytosolic extracts (30 μg) were combined with NuPAGE 4X LDS sample buffer and NuPAGE 10X sample reducing agent (Invitrogen) and put in heat block at 99 °C for 5 minutes. 
XI. Compound Treatment for ELISA and PCR
DU-145 cells were seeded into 24-well plates at a cell density of 2 × 10 5 cells/well. The plate was dosed with compounds 10-12 for 24 hours. The cells were induced with TNF-α (117 ng/mL) six hours after the initial dosing, resulting in an 18 hour induction.
XII. IL-8 Enzyme-Linked Immunosorbent Assays
A human IL-8 ELISA kit (Thermo Scientific, EH2IL82) was used to quantitate secreted IL-8 protein levels in NF-κB-induced DU-145 cells treated with 10-12. Following the dosing and induction of DU-145 S12 cells (described above), cell media (500 µL) was collected from each treated well and stored at -20 °C until analysis. Immediately prior to analysis, samples were centrifuged at maximum speed (21,000 x g) for 1 minute and then secreted IL-8 protein levels were measured for each sample according to vendor instructions. The absorbance of each sample at 450 nm and 550 nm was collected following addition of the substrate stop solution using a Molecular Devices SpectraMax M2 plate reader. The standard curve was fitted using a 4-parameter logistic (4-PL) algorithm in GraphPad Prism (v. 5.0) software. Unknown samples were plotted against the standard curve to yield IL-8 protein concentrations in pg/mL. Triplicate biological replicates were performed and each bar represents at least 6 individual wells. The data shown in Figure 4 is mean ± SEM, which was calculated from mean values of each of the three biological replicates. Statistical analyses were performed in Microsoft excel and data was plotted using
GraphPad Prism (v. 5.0) software.
XIII. mRNA Isolation and Purification
RNeasy Plus Micro Kits (Qiagen, 74034) and QIAshredders (Qiagen, 79654) were used to isolate and purify mRNA from DU-145 cells. Following compound dosing, NF-κB induction, and harvesting of the cell media (described above), cell monolayers were washed with PBS (1X) and then lysed according to the method described in the RNeasy Plus Micro Kit (β-Mercaptoethanol supplement was included). The samples were then homogenized using QIAshredders according to vendor instructions. mRNA was isolated and purified using the RNease Plus Micro Kit and eluted in RNase-free water (14 μL). RNA samples were immediately stored at -80 °C.
XIV. Reverse Transcription (RT) & Polymerase Chain Reaction (PCR) Assays
The RNA concentration and purity of each sample were determined using a NanoDrop instrument (Thermo Scientific). RNA samples with A 260 /A 280 ratios ≥ 1.9 were used in PCR assays. The concentration of each mRNA sample within a biological experiment was normalized to the value obtained from the sample with the lowest measured mRNA concentration. Reverse transcription of mRNA into cDNA was carried out using the QuantiTect Reverse Transcription Kit (Qiagen, 205311).
Template mRNA was added to gDNA Wipeout Buffer (7X) and RNase-free water for a total volume of 14 μL (less than 1 μg of mRNA was added to each sample). Samples were then incubated at 42 °C for 2 minutes (Bio-Rad T100 thermal cycler) and then immediately placed on ice. Next, the entire contents of the previous mix were added to 6 μL of reverse-transcription master mix, and mRNA was reverse An aliquot of the resulting PCR products (2 μL) was added to loading buffer (8 μL; recipe for loading buffer: 10 mg of orange G, 10 mg of bromophenol blue sodium salt, and 10 mg of xylene cyanol FF in 6 mL of formamide). The samples were then electrophoresed on a 1% agarose gel made in 0.5% TBE buffer (10X TBE components (to make 1 L): 108 g tris base, 55 g boric acid, and 7.4 g EDTA in distilled
and deionized water). The agarose gel was stained using SYBR Gold nucleic acid gel stain (Invitrogen) and then visualized using the Typhoon FLA 7000 (GE Healthcare). Gels were analyzed using ImageQuant TL software (GE, version 7.0).
XV. HPLC and NMR Michael Acceptor Assays
A previously described NMR assay was performed to measure the reactivity of 10 towards thiols. For analysis of thiol reactivity of 10 by HPLC, the protocol described above was repeated, except the PBS solution was prepared in distilled water. After 10 minutes, trifluoroacetic acid (50 μL, 80% v/v TFA in distilled H 2 O) was added to the reaction mixture and the reaction products were separated using an Agilent 1200 series instrument equipped with a diode array detector and a Zorbax SB-C18 column (4.6
x 150 mm, 3.5 μm, Agilent Technologies) at 23 ºC. The mobile phase comprised 0.1% TFA in water (0 to 10 min), followed by 0 to 85% 0.1% TFA in CH 3 CN (10 to 24 min) at a flow-rate of 1.0 mL/min. The major peak (t R = 11.3 min) was collected and analyzed by negative ESI mass spectrometry confirming formation of 13. 
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